Abbott Parenteral Manufacturing Is Subject Of FDA Warning Letter
Executive Summary
Abbott's discussions with FDA over the good manufacturing practices compliance of its in vitro diagnostics business also included discussions of the GMP status of its large- and small-volume parenteral drug manufacturing operations.